EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapalink-1 reveals an mTOR- and p53-regulated transcriptional program in Neuro-2a cells

Joel Karikari Nyarkoh, Matthew Wolan iD, Eric Barrett iD, Aidan M Sokolov, Rachel A Lyman, Trudy F C Mackay, David M Feliciano iD

Biology Open · 15.10.2026 · 15 (10)

DOI: 10.1242/bio.062902 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biology Open, online erschienen am 21.10.2026. Verfasst von Joel Karikari Nyarkoh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Clemson University, Clemson, SC 29634, USA. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, TOR Serine-Threonine Kinases, Sirolimus, Transcription, Genetic. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Clemson University, American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mammalian target of rapamycin (mTOR) is the catalytic subunit of two exclusive complexes referred to as mTORC1 and mTORC2. The mTORCs phosphorylate different substrates and control different cellular processes. Inhibitors of mTORC1 include rapamycin analogs (rapalogs) that are useful in many clinical settings. However, they have failed in cancer trials potentially due to resistance mechanisms and incomplete inhibition of mTORC1 phosphorylation of select substrates. The rapamycin sensitivity of mTORC1 substrates is likely encoded by the substrate's primary amino acid sequence determinants and the ability of substrates to fit into the catalytic region of the kinase super-complex. Thus, some mTORC1 substrates are unaffected by rapalogs. Second-generation ATP-binding pocket inhibitors are mTOR catalytic inhibitors that bind in an ATP-competitive manner. Torin1 is an exemplary second-generation mTOR inhibitor with superior inhibition of mTORC1 substrates, including 4EBP. However, these inhibitors fail to demonstrate selectivity between mTORC1 and mTORC2. Third-generation bisteric mTORC1 inhibitors are exemplified by Rapalink-1, which links a rapamycin moiety to the ATP-competitive inhibitor MLN-0128. Here, we report that Rapalink-1 inhibits three mTORC1 substrates, including 4EBP and Ulk1, which are rapamycin insensitive. To provide additional mechanistic insight into the Rapalink-1 mechanism of action, RNA sequencing of Neuro-2a cells treated with Rapalink-1 was performed. Rapalink-1 caused transcriptomic changes indicative of reductions in the mTOR pathway and brain development. Many transcripts contained a p53 binding site, and consistent with this finding, we also observed reduced levels of p53. These results confirm and expand upon the Rapalink-1 mechanism of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53TOR Serine-Threonine KinasesSirolimusTranscription, GeneticGene Expression RegulationAnimalsMiceMechanistic Target of Rapamycin Complex 1MTOR InhibitorsCell Line, TumorPhosphorylationCell LineSignal Transduction

Stichwörter der Autor:innen

CancerRapalink-1mTORmTORC1

Substanzen

Tumor Suppressor Protein p53TOR Serine-Threonine KinasesSirolimusMechanistic Target of Rapamycin Complex 1MTOR Inhibitors

Autor:innen und Institutionen

  • Department of Biological Sciences, Clemson University, Clemson, SC 29634, USA.
  • Department of Biochemistry and Genetics, Clemson University, Clemson, SC 29634, USA.
  • Institute for Human Genetics, Clemson University, Greenwood, SC 29646, USA.

ORCID-Profile: Matthew Wolan, Eric Barrett, David M Feliciano

Förderung

  • NIGMS NIH HHS
  • Clemson University
  • American Cancer Society

Zitieren

APA

Nyarkoh, J. K., Wolan, M., Barrett, E., Sokolov, A. M., Lyman, R. A., Mackay, T. F. C., & Feliciano, D. M. (2026). Rapalink-1 reveals an mTOR- and p53-regulated transcriptional program in Neuro-2a cells. Biology Open, 15(10). https://doi.org/10.1242/bio.062902

Vancouver

Nyarkoh JK, Wolan M, Barrett E, Sokolov AM, Lyman RA, Mackay TFC, et al. Rapalink-1 reveals an mTOR- and p53-regulated transcriptional program in Neuro-2a cells. Biology Open. 2026;15(10). doi:10.1242/bio.062902

BibTeX
@article{Nyarkoh2026,
  author = {Nyarkoh, Joel Karikari and Wolan, Matthew and Barrett, Eric and Sokolov, Aidan M and Lyman, Rachel A and Mackay, Trudy F C and Feliciano, David M},
  title = {Rapalink-1 reveals an mTOR- and p53-regulated transcriptional program in Neuro-2a cells},
  journal = {Biology Open},
  year = {2026},
  volume = {15},
  number = {10},
  doi = {10.1242/bio.062902}
}
Kostenlos starten →